| Print
Swedish Orphan Biovitrum AB (SOBI)
This share can be held in a Dealing accountSIPP
Company profile
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Address
Strandbergsgatan 49,
Stockholm
SWE
SE-112 76
Telephone
+1 468 6972000
Forecast key dates
| Name | Key Date |
|---|---|
| Swedish Orphan Biovitrum AB Third Quarter Earnings Result for 2026 | 2026-10-27T00:00:00 |
| Swedish Orphan Biovitrum AB Third Quarter Earnings Conference Call for 2026 | 2026-10-27T00:00:00 |
| Swedish Orphan Biovitrum AB Second Quarter Earnings Result for 2026 | 2026-07-16T00:00:00 |
| Swedish Orphan Biovitrum AB Second Quarter Earnings Conference Call for 2026 | 2026-07-16T00:00:00 |
| Swedish Orphan Biovitrum AB Annual General Meeting for 2026 | 2026-05-06T00:00:00 |
| Swedish Orphan Biovitrum AB First Quarter Earnings Result for 2026 | 2026-04-28T00:00:00 |
| Swedish Orphan Biovitrum AB First Quarter Earnings Conference Call for 2026 | 2026-04-28T00:00:00 |
| Swedish Orphan Biovitrum AB Annual Report for 2025 | 2026-03-31T00:00:00 |
| Swedish Orphan Biovitrum AB Fourth Quarter Earnings Result for 2025 | 2026-02-05T00:00:00 |
| Swedish Orphan Biovitrum AB Fourth Quarter Earnings Conference Call for 2025 | 2026-02-05T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Swedish Orphan Biovitrum AB Third Quarter Earnings Conference Call for 2025 | 2025-10-23T13:00:00 |
| Swedish Orphan Biovitrum AB Third Quarter Earnings Results for 2025 | 2025-10-23T08:00:00 |
| Swedish Orphan Biovitrum AB Second Quarter Earnings Conference Call for 2025 | 2025-07-16T14:00:00 |
| Swedish Orphan Biovitrum AB Second Quarter Earnings Results for 2025 | 2025-07-16T08:00:00 |
| Swedish Orphan Biovitrum AB Annual General Meeting for 2025 | 2025-05-08T10:00:00 |
| Swedish Orphan Biovitrum AB First Quarter Earnings Result for 2025 | 2025-04-29T00:00:00 |
| Swedish Orphan Biovitrum AB First Quarter Earnings Conference Call for 2025 | 2025-04-29T00:00:00 |
| Swedish Orphan Biovitrum AB Annual Report for 2024 | 2025-03-31T00:00:00 |
| Swedish Orphan Biovitrum AB Fourth Quarter Earnings Conference Call for 2024 | 2025-02-05T14:30:00 |
| Swedish Orphan Biovitrum AB Fourth Quarter Earnings Results for 2024 | 2025-02-05T08:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.